Advancing the global Phase 3 clinical development of the oral, once-daily, fixed-dose combination of bemnifosbuvir (nucleotide NS5B polymerase inhibitor) and ruzasvir (NS5A inhibitor) for the treatment of chronic hepatitis C virus (HCV) infection.

Expected impact: Aims to establish a best-in-class, short-duration, pan-genotypic oral cure for HCV with a high barrier to resistance and low risk of drug-drug interactions.

Expanding the clinical pipeline into hepatitis E virus (HEV) treatment by developing AT-587, a proprietary oral nucleotide analog designed to treat chronic HEV infection in immunocompromised patients.

Expected impact: Addresses a significant unmet medical need for high-risk populations (such as solid organ transplant recipients) where no approved direct-acting antiviral therapies currently exist.

Conducting a comprehensive review of strategic opportunities with the assistance of an independent global investment bank to identify potential avenues to enhance shareholder value.

Expected impact: Explores potential strategic partnerships, acquisitions, mergers, or other business combinations, particularly surrounding the global commercialization of the HCV combination regimen.

Implementing disciplined cost-saving measures, including a workforce reduction of approximately 25% executed in early 2025, to optimize resource allocation and extend the operational cash runway.

Expected impact: Expected to generate approximately $15 million in cost savings through 2027, helping to fund late-stage clinical programs without immediate financing risk.